{"id":28004,"date":"2014-08-12T09:47:59","date_gmt":"2014-08-12T13:47:59","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28004"},"modified":"2014-08-12T09:47:59","modified_gmt":"2014-08-12T13:47:59","slug":"pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004","title":{"rendered":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/12\/2014 (wallstreetpr) \u2013 Biodefense Company, <b>PharmAthene, inc. (NYSEMKT:PIP)<\/b>, may earn up to $500 million from a dispute involving <strong>SIGA Technologies, Inc. (NASDAQ:SIGA)<\/strong> on a smallpox drug; this is after a judge ruled on the same. Siga may be forced to pay up to <a href=\"http:\/\/www.bloomberg.com\/news\/2014-08-11\/pharmathene-to-share-up-to-500-million-in-smallpox-drug-profits.html?cmpid=yhoo\" target=\"_blank\">$500 million<\/a> in the form of lost profits under a licensing accord ruled by Delaware Chancery judge Donald Parsons.<\/p>\n<p style=\"text-align: justify;\"><b>Court To Decide On The Settlement Package<\/b><\/p>\n<p style=\"text-align: justify;\">Judge Parsons must now decide on whether to order Siga to pay up to $500 million as damages at the back of the Siga stating that PharmAthene, inc. (NYSEMKT:PIP) does not deserve more than $50 million. John Lewis, an investor at Siga and former president of Gardner Lewis Asset Management is of the opinion that the judge must decide on what is reasonable based on the expectations of the total sales of the drug. Lewis has reiterated an award of more than $500 million would be absurd in this case.<\/p>\n<p style=\"text-align: justify;\">The case might be pushed for review to the highest court in Delaware if the ongoing tussle between the two companies does not come to an amicable end in the lower court. The contest marks a new chapter in a six-year case involving a drug that was perceived&#8217; as an effective drug of fighting smallpox mainly associated with terrorist attacks.<\/p>\n<p style=\"text-align: justify;\">PharmAthene stock continues to be the main beneficiary of the ongoing tussle having risen by 43.20% on Monday trading sessions after it emerged it might earn up to $500 million in damages. Siga, on the other hand, sunk by 39%, its single biggest drop in more than three years<\/p>\n<p style=\"text-align: justify;\">PharmAthene, inc. (NYSEMKT:PIP) had sued Siga in 2006 claiming rights to an antiviral drug that formed part of the licensing agreement. PharmAthene at the time claimed it deserved up to $1 billion in potential sales of the drug as it helped fund its development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/12\/2014 (wallstreetpr) \u2013 Biodefense Company, PharmAthene, inc. (NYSEMKT:PIP), may earn up to $500 million from a dispute involving SIGA Technologies, Inc. (NASDAQ:SIGA) on [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":28005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7837,7825,7822,7821,7820,7824,7823],"stock_ticker":[],"class_list":["post-28004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-judge-parsons","tag-nasdaqsiga","tag-nysemktpip","tag-pharmathene-inc","tag-pharmathene-inc-nysemktpip","tag-siga-technologies-inc","tag-siga-technologies-inc-nasdaqsiga","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/12\/2014 (wallstreetpr) \u2013 Biodefense Company, PharmAthene, inc. (NYSEMKT:PIP), may earn up to $500 million from a dispute involving SIGA Technologies, Inc. (NASDAQ:SIGA) on [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-12T13:47:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"249\" \/>\n\t<meta property=\"og:image:height\" content=\"202\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug\",\"datePublished\":\"2014-08-12T13:47:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg\",\"keywords\":[\"Judge Parsons\",\"NASDAQ:SIGA\",\"NYSEMKT:PIP\",\"PharmAthene inc.\",\"PharmAthene inc. (NYSEMKT:PIP)\",\"SIGA Technologies Inc.\",\"SIGA Technologies Inc. (NASDAQ:SIGA)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\",\"name\":\"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg\",\"datePublished\":\"2014-08-12T13:47:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg\",\"width\":249,\"height\":202},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004","og_locale":"en_US","og_type":"article","og_title":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR","og_description":"Boston, MA 08\/12\/2014 (wallstreetpr) \u2013 Biodefense Company, PharmAthene, inc. (NYSEMKT:PIP), may earn up to $500 million from a dispute involving SIGA Technologies, Inc. (NASDAQ:SIGA) on [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-12T13:47:59+00:00","og_image":[{"width":249,"height":202,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug","datePublished":"2014-08-12T13:47:59+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg","keywords":["Judge Parsons","NASDAQ:SIGA","NYSEMKT:PIP","PharmAthene inc.","PharmAthene inc. (NYSEMKT:PIP)","SIGA Technologies Inc.","SIGA Technologies Inc. (NASDAQ:SIGA)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004","name":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg","datePublished":"2014-08-12T13:47:59+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/index12.jpg","width":249,"height":202},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmathene-inc-nysemktpip-se-to-earn-500million-from-a-smallpox-drug-28004#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"PharmAthene, inc. (NYSEMKT:PIP) Se to Earn $500Million from a Smallpox Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28004"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28004\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/28005"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28004"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}